The EU-funded CardioReGenix project focuses on technological innovations for the treatment of heart failure and myocardial ischemia. The goal is to overcome obstacles in cardiovascular disease (CVD) gene therapy, capitalising on robust preliminary data and multi-disciplinary consortium know-how in vector development, preclinical and clinical cardiology, business development and clinical translation.
According to WHO estimates, 17.7 million people die each year from CVD, which constitutes more than 30 % of all deaths worldwide. Recent advances in biomedical research improved our understanding of the molecular and cellular mechanisms of the disease and introduced efficient and safer gene therapy vectors for the development of next-generation advanced therapy medicinal products (ATMPs) for CVD.
At ASPHALION we are in charge of the #Regulatory pathway, including scientific consultations with Regulatory Agencies, and the development of the necessary #dossiers which will be used to secure #clinicaltrial authorisation following the #CardioReGenix project and our expert Laura Mendieta attended the meeting to update on the latest regulatory developments.
For further information, you can contact us at: info@asphalion.com
